1276.HK
600276.SHG
111 does healthcare

Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) said on Sunday that executive director and senior vice president Sun Jieping will sell up to 476,700 of his A-shares in the company for personal reasons. Hengrui said Sun, who is the company’s deputy general manager, will sell the stock via centralized bidding during the three months starting 15 trading days after the disclosure.

Sun holds about 1.9 million Hengrui shares, accounting for roughly 0.029% of its total share capital, predominantly acquired through equity incentive plans. His planned sale represents about 0.007% of the company’s total share capital.

Hengrui is listed in Shanghai and made a second listing in Hong Kong at the end of last month. The offering was oversubscribed by about 454 times, with the international portion oversubscribed by 16 times. It priced its Hong Kong shares at HK$44.05 each, raising nearly HK$10 billion ($1.27 billion).

Shares of Hengrui opened down 0.5% at HK$57.50 on Monday. The stock is up around 30% from its Hong Kong listing price.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

World Road does logistics

World Road faces bumpy path to Nasdaq listing

The cross-border logistics company has quadrupled the size of its IPO in response to new rules seeking to stamp out suspicious new Chinese listings, seeking to raise $33 million Key…
ASR looks to climb up the value chain

Volume chipmaker ASR looks to climb up the value chain

The global leader in cellular connectivity chips has filed for a Hong Kong listing as it accelerates its push into the higher-margin business of specialized ASIC chips Key Takeaways: ASR…
Tinci IPO gets CSRC approval

Is Tinci Materials limping to a Hong Kong IPO?

China’s securities regulator has given the green light to the battery materials maker’s Hong Kong listing application, but only after a year of scrutiny Key Takeaways: Tinci Materials has been…